Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057343 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00057343: Clinical Trial Phase 3 study, sponsored by Biogen.
NCT00057343 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057343, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.
Interventions
- DRUG Zevalin (ibritumomab tiuxetan)
- DRUG Rituxan (rituximab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-03 |
| Phase | Phase 3 |
Why NCT00057343 stopped before completion
NCT00057343 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which Zevalin (ibritumomab tiuxetan) is the first listed.
NCT00057343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057343 about?
NCT00057343 is a clinical study titled "Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma". The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.
What is the current status of trial NCT00057343?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2003-03.
What interventions are being tested in trial NCT00057343?
The interventions under investigation include: Zevalin (ibritumomab tiuxetan) (DRUG), Rituxan (rituximab) (DRUG).
Who is sponsoring clinical trial NCT00057343?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00057343's enrollment target sits among peer trials
400 922nd of 2000 higher than 1,039 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia